Primary gynecologic neuroendocrine carcinomas (gNECs) are a heterogeneous spectrum of rare and highly aggressive neoplasms, accounting for about 2% of all gynecologic malignancies, which mostly resemble the small cell lung carcinoma (SCLC). Due to the lack of standardized treatment guidelines, their management poses a noteworthy clinical challenge. Currently, cumulative data retrieved from the management of SCLC and from retrospective studies supports a multimodality strategy, based on surgery, chemotherapy, and radiotherapy. Nevertheless, the prognosis remains poor and recurrences are extremely frequent. Hence, there is an urgent need for novel treatment options and promising molecular targets. Recently, there has been an increasing interest on the potential role of immune checkpoint inhibitors, especially in the recurrent setting. However, only scant evidence exists and there is still a long road ahead. A solid collaboration between gynecologists and oncologists worldwide is required to improve the treatment of these puzzling tumors.

The puzzle of gynecologic neuroendocrine carcinomas: State of the art and future directions / Caruso, Giuseppe; Sassu, CAROLINA MARIA; Tomao, Federica; DI DONATO, Violante; Perniola, Giorgia; Fischetti, Margherita; BENEDETTI PANICI, Pierluigi; Palaia, Innocenza. - In: CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. - ISSN 1879-0461. - 162:(2021), p. 103344. [10.1016/j.critrevonc.2021.103344]

The puzzle of gynecologic neuroendocrine carcinomas: State of the art and future directions

Giuseppe Caruso
;
Carolina Maria Sassu;Federica Tomao;Violante Di Donato;Giorgia Perniola;Margherita Fischetti;Pierluigi Benedetti Panici;Innocenza Palaia
2021

Abstract

Primary gynecologic neuroendocrine carcinomas (gNECs) are a heterogeneous spectrum of rare and highly aggressive neoplasms, accounting for about 2% of all gynecologic malignancies, which mostly resemble the small cell lung carcinoma (SCLC). Due to the lack of standardized treatment guidelines, their management poses a noteworthy clinical challenge. Currently, cumulative data retrieved from the management of SCLC and from retrospective studies supports a multimodality strategy, based on surgery, chemotherapy, and radiotherapy. Nevertheless, the prognosis remains poor and recurrences are extremely frequent. Hence, there is an urgent need for novel treatment options and promising molecular targets. Recently, there has been an increasing interest on the potential role of immune checkpoint inhibitors, especially in the recurrent setting. However, only scant evidence exists and there is still a long road ahead. A solid collaboration between gynecologists and oncologists worldwide is required to improve the treatment of these puzzling tumors.
2021
Neuroendocrine tumors; Neuroendocrine carcinoma; Gynecologic tract; Small cell carcinoma; Immune checkpoint inhibitors
01 Pubblicazione su rivista::01a Articolo in rivista
The puzzle of gynecologic neuroendocrine carcinomas: State of the art and future directions / Caruso, Giuseppe; Sassu, CAROLINA MARIA; Tomao, Federica; DI DONATO, Violante; Perniola, Giorgia; Fischetti, Margherita; BENEDETTI PANICI, Pierluigi; Palaia, Innocenza. - In: CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. - ISSN 1879-0461. - 162:(2021), p. 103344. [10.1016/j.critrevonc.2021.103344]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1667522
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
social impact